Dutogliptin
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Dutogliptin
- DrugBank Accession Number
- DB11723
- Background
Dutogliptin has been investigated for the treatment of Diabetes Mellitus, Type II.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 241.1
Monoisotopic: 241.159772 - Chemical Formula
- C10H20BN3O3
- Synonyms
- Dutogliptin
- External IDs
- PHX1149
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Dutogliptin is a potent and selective inhibitor of DPP4, a serine protease that has emerged as an important target for the treatment of type 2 diabetes. Inhibiting DPP4 increases the physiological levels of regulatory peptides, such as GLP-1, an important modulator of insulin response and digestion.
Target Actions Organism UDipeptidyl peptidase 4 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
10-13 hours
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcarbose The risk or severity of hypoglycemia can be increased when Acarbose is combined with Dutogliptin. Acebutolol The therapeutic efficacy of Dutogliptin can be increased when used in combination with Acebutolol. Acetazolamide The therapeutic efficacy of Dutogliptin can be increased when used in combination with Acetazolamide. Acetohexamide Dutogliptin may increase the hypoglycemic activities of Acetohexamide. Acetyl sulfisoxazole The therapeutic efficacy of Dutogliptin can be increased when used in combination with Acetyl sulfisoxazole. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Dutogliptin Tartrate 79QH89EV9M 890402-81-0 SVWHNLVZPGXBNS-MHDNXTQBSA-N
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Alpha amino acid amides
- Alternative Parents
- N-acylpyrrolidines / Tertiary carboxylic acid amides / Boronic acids / Organic metalloid salts / Dialkylamines / Azacyclic compounds / Organic oxides / Monoalkylboranes / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Aliphatic heteromonocyclic compound / Alkylborane / Alpha-amino acid amide / Amine / Azacycle / Boronic acid / Boronic acid derivative / Carbonyl group / Carboxamide group / Hydrocarbon derivative
- Molecular Framework
- Aliphatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 38EAO245ZX
- CAS number
- 852329-66-9
- InChI Key
- DVJAMEIQRSHVKC-BDAKNGLRSA-N
- InChI
- InChI=1S/C10H20BN3O3/c15-10(7-13-8-3-4-12-6-8)14-5-1-2-9(14)11(16)17/h8-9,12-13,16-17H,1-7H2/t8-,9+/m1/s1
- IUPAC Name
- [(2R)-1-(2-{[(3R)-pyrrolidin-3-yl]amino}acetyl)pyrrolidin-2-yl]boronic acid
- SMILES
- OB(O)[C@@H]1CCCN1C(=O)CN[C@@H]1CCNC1
References
- General References
- O'Farrell AM, van Vliet A, Abou Farha K, Cherrington JM, Campbell DA, Li X, Hanway D, Li J, Guler HP: Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects. Clin Ther. 2007 Aug;29(8):1692-705. [Article]
- External Links
- PubChem Compound
- 11253490
- PubChem Substance
- 347828085
- ChemSpider
- 9428517
- ZINC
- ZINC000169746730
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Type 2 Diabetes Mellitus 1 3 Not Yet Recruiting Treatment ST Segment Elevation Myocardial Infarction (STEMI) 1 3 Terminated Treatment Impaired Renal Function / Type 2 Diabetes Mellitus 1 3 Terminated Treatment Type 2 Diabetes Mellitus 6 2 Completed Treatment Acute Myocardial Infarction (AMI) / Acute Myocardial Ischemia / ST Segment Elevation Myocardial Infarction (STEMI) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 6.93 mg/mL ALOGPS logP -1.1 ALOGPS logP -2.4 Chemaxon logS -1.5 ALOGPS pKa (Strongest Acidic) 8.63 Chemaxon pKa (Strongest Basic) 10.1 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 84.83 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 58.91 m3·mol-1 Chemaxon Polarizability 25.94 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsDipeptidyl peptidase 4
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Virus receptor activity
- Specific Function
- Cell surface glycoprotein receptor involved in the costimulatory signal essential for T-cell receptor (TCR)-mediated T-cell activation. Acts as a positive regulator of T-cell coactivation, by bindi...
- Gene Name
- DPP4
- Uniprot ID
- P27487
- Uniprot Name
- Dipeptidyl peptidase 4
- Molecular Weight
- 88277.935 Da
Drug created at October 20, 2016 20:42 / Updated at February 21, 2021 18:53